Ahmed Zakari, MD
Hematology · Altamonte Springs, FLNPI 1447268297
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $296,688 of the $383,182 with a category attached, or 77.4%. 40 manufacturers reported payments, led by Incyte Corporation at 41.7% of the total. 2025 is the largest year on record at $104,691, 3.3 times the $31,854 reported in 2019. Among hematology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $798.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$160K
- AstraZeneca$58K
- Taiho Oncology, Inc.$37K
- Amgen$32K
- Geron Corporation$18K
- Bayer$18K
- plus $59K from 34 others
Across 122 payments — averaging $7571.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$435K
- AbbVie$209K
- AstraZeneca$130K
- Bristol Myers Squibb$63K
- Genentech, Inc.$31K
- E.r. Squibb & Sons, L.L.C.$28K
- plus $27K from 3 others
What the payments were for
- Consulting fees$37,71110%
- Speaking & faculty fees$296,68877%
- Travel & lodging$34,1809%
- Food & beverage$14,1174%
- Education$4850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$383,182 in reported general payments places this provider in the 95th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 32 | $399,843 |
| LenvimaLenvatinib Mesylate | 13 | $296,712 |
| TasignaNilotinib Hcl | 12 | $226,068 |
| CalquenceAcalabrutinib Maleate | 14 | $205,595 |
| InqoviDecitabine/Cedazuridine | 12 | $96,009 |
| Fentanyl | 44 | $3,939 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 75 | $2,031 |
| Oxycodone Hcl | 96 | $1,953 |
| Ondansetron OdtOndansetron | 58 | $1,783 |
| Morphine Sulfate ErMorphine Sulfate | 39 | $1,171 |
| CholestyramineCholestyramine (With Sugar) | 11 | $1,030 |
| Tramadol Hcl | 87 | $968 |
| Ondansetron Hcl | 27 | $963 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $810 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 31 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Lonsurf, Inqovi | $37,336 | $495,85244 claims |
| Eisai Inc.Lenvima | $123 | $296,71213 claims |
| NovartisTasigna | $3,606 | $226,06812 claims |
| AstraZenecaCalquence | $58,275 | $205,59514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 hematology providers in Florida.
Other hematology in Altamonte Springs
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Alex Mejia GarciaVero Beach$302K
- Doris HansenTampa$141K
- Juan VarelaOrlando$131K
- Firas El ChaerMiami$105K
- Philip PancariOrlando$70K
- Melissa AlsinaTampa$64K
- Terrence BradleyMiami$53K
- Alan ListTampa$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.